Recent clinical trial data on the efficacy of immunotherapy show that anti-PD-1/PD-L1 inhibitors appear to be beneficial for subgroups of patients with advanced gastric or esophageal cancer who have undergone a variety of systemic chemotherapy19. This evidence concerns the gene CD274 and esophageal cancer.